SLC2A11: A Potential Drug Target Or Biomarker (G66035)

Target Name: SLC2A11

NCBI ID: G66035

SLC2A11

SLC2A11: A Potential Drug Target Or Biomarker

SLC2A11, also known as Suretide, is a member of the Sodium Chloride Transporter (SCT) family, which is a subfamily of the SLC (Sodium Chloride) Transporter gene family. SLC2A11 is a protein that is expressed in various tissues and organs, including the brain, heart, liver, and kidney. It plays a critical role in the transport of sodium ions into these tissues and is involved in a number of physiological processes, including blood pressure, water balance, and glucose metabolism.

SLC2A11 is a type of transmembrane protein that is composed of an extracellular region, a transmembrane segment, and an intracellular segment. The extracellular region consists of a single transmembrane protein that is involved in the regulation of sodium ion transport. The transmembrane segment consists of four transmembrane proteins that are involved in the regulation of sodium ion transport. The intracellular segment consists of a protein that is involved in the regulation of sodium ion transport in the brain.

SLC2A11 is involved in a number of physiological processes that are critical for the survival and proper functioning of the body. For example, SLC2A11 is involved in the regulation of blood pressure, which is essential for maintaining proper blood flow to the brain and other tissues. SLC2A11 is also involved in the regulation of water balance, which is essential for maintaining the proper concentration of water in the body and preventing dehydration. Additionally, SLC2A11 is involved in the regulation of glucose metabolism, which is essential for the proper functioning of the brain and other tissues.

SLC2A11 is also a potential drug target or biomarker. Researchers have identified SLC2A11 as a potential drug target because of its involvement in a number of physiological processes that are critical for the survival and proper functioning of the body. SLC2A11 has also been shown to be involved in a number of diseases, including heart disease, diabetes, and hypertension. Therefore, targeting SLC2A11 with drugs or other therapeutic agents may be an effective way to treat these diseases.

In addition to its potential drug-targeting properties, SLC2A11 is also a potential biomarker for a number of diseases. For example, SLC2A11 has been shown to be elevated in the blood of patients with heart disease, which may be an indication of increased sodium ion transport and increased risk of heart disease. Similarly, SLC2A11 has been shown to be elevated in the blood of patients with diabetes, which may be an indication of increased sodium ion transport and increased risk of diabetes-related complications.

Overall, SLC2A11 is a transmembrane protein that is involved in the regulation of sodium ion transport and is critical for the survival and proper functioning of the body. As a potential drug target or biomarker, SLC2A11 may be an effective way to treat a number of diseases. Further research is needed to fully understand the role of SLC2A11 in the regulation of sodium ion transport and its potential as a drug target or biomarker.

Protein Name: Solute Carrier Family 2 Member 11

Functions: Facilitative glucose transporter

The "SLC2A11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC2A11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets